Drug
Devimistat clinical trials
Also written CPI-613.
- studies test it
- 32
- open now
- 0
- in phase 3
- 2
- first study started
- 2008
How studies write it
Studies that test it under each name
Name
Development codes
- CPI-613
- 29
Studies by the year they started
32 studies that test it; most in 2013 (7)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2013 | 7 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 1 |
| 2018 | 6 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 21
- Phase 2
- 18
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 22
Wake Forest University Health Sciences (16) · Cornerstone Pharmaceuticals (10) · University of Michigan Rogel Cancer Center (2) · Memorial Sloan Kettering Cancer Center (1) · David Bajor, MD (1) · Medical College of Wisconsin (1) · Sidney Kimmel Cancer Center at Thomas Jefferson University (1)
Often tested with
Tested in the same studies.
Cytarabine (4) · Mitoxantrone (3) · Bendamustine (3) · Modified FOLFIRINOX Regimen (3) · Hydroxychloroquine (2) · Fluorouracil (1) · Rituximab (1) · Metformin (1)
Studies
Open first, then newest update. How each study uses devimistat is read from its arms, and is right about nine times in ten.
Testing it · 32
- A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk TranslocationsCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT03793140Written as CPI-613
- Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)TerminatedPhase 1/2University of Michigan Rogel Cancer CenterNCT04203160Written as CPI 613
- CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic AdenocarcinomaTerminatedPhase 1Medical College of WisconsinNCT05325281Written as CPI-613® (Dose level -1.0 250 mg/m^2)
- CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin LymphomaTerminatedPhase 2Wake Forest University Health SciencesNCT04217317Written as CPI 613
- CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic CancerWithdrawnPhase 2Sidney Kimmel Cancer Center at Thomas Jefferson UniversityNCT03374852Written as CPI-613
- CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic CancerCompletedPhase 1/2David Bajor, MDNCT03699319Written as CPI 613
- CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous TherapyTerminatedPhase 2Wake Forest University Health SciencesNCT01902381Written as 6,8-bis(benzylthio)octanoic acid
- CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic SarcomaCompletedPhase 1Wake Forest University Health SciencesNCT02484391Written as 6,8-Bis(benzylthio)octanoic Acid
- CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)WithdrawnPhase 2Wake Forest University Health SciencesNCT05854966Written as CPI 613
- Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic CancerWithdrawnPhase 2Cornerstone PharmaceuticalsNCT06518538Written as CPI-613, modified Folfirinox
- CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin LymphomaCompletedPhase 1Wake Forest University Health SciencesNCT02168140Written as 6,8-bis(benzylthio)octanoic acid
- CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal CancerWithdrawnPhase 1Cornerstone PharmaceuticalsNCT05070104Written as CPI-613
- CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by SurgeryCompletedPhase 1Wake Forest University Health SciencesNCT02232152Written as 6,8-bis(benzylthio)octanoic acid
- Trial of Devimistat in Combination With Modified FOLFIRINOX in Patients With Metastatic Adenocarcinoma of the PancreasWithdrawnPhase 1/2University of Michigan Rogel Cancer CenterNCT05926206Written as Devimistat
- CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic CancerCompletedPhase 1Wake Forest University Health SciencesNCT01835041Written as 6,8-bis(benzylthio)octanoic acid
- To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft TissueCompletedPhase 1/2Cornerstone PharmaceuticalsNCT04593758Written as CPI-613 + Hydroxychloroquine
- Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AMLTerminatedPhase 3Cornerstone PharmaceuticalsNCT03504410Written as CPI-613 + High Dose Cytarabine and Mitoxantrone
- Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the PancreasCompletedPhase 3Cornerstone PharmaceuticalsNCT03504423Written as CPI 613, mFolfirinox
- CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic SyndromeWithdrawnPhase 1/2Wake Forest University Health SciencesNCT03929211Written as CPI-613
- CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By SurgeryCompletedPhase 1/2Wake Forest University Health SciencesNCT01766219Written as 6,8-bis(benzylthio)octanoic acid
See all 32 studies that test devimistat →
Given in every arm · 1 — devimistat is usual care beside what is tested
Codes
What other systems call devimistat · ClinicalTrials.gg INT005953
- MeSH (NLM) C568850devimistatOne source NLM
- UNII (FDA) E76113IR49DEVIMISTATConfirmed FDA, NLM, Wikidata
- Wikidata Q27276958devimistatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C80039DevimistatOne source FDA
- DrugBank DB12109One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C568850 | devimistat | One source NLM |
| UNII (FDA) | E76113IR49 | DEVIMISTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27276958 | devimistat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C80039 | Devimistat | One source FDA |
| DrugBank | DB12109 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.